On Monday, Shares of Tableau Software Inc (NYSE:DATA), gained 1.77% to $84.47.
Deloitte Consulting, has signed an alliance with Tableau Software (DATA), a global leader in rapid-fire, easy-to-use business analytics software.
“Tableau solutions will enhance Deloitte’s ability to deliver self-service analytics capabilities to our enterprise customers,” said Richard Starnes, principal, Deloitte Consulting LLP. “With Deloitte’s planned advisory and industry experience, our joint customers can transform their businesses by implementing an agile, self-reliant data driven culture.”
The alliance will expand on Deloitte’s breadth of information administration services and go beyond the traditional business intelligence (BI) domain by addressing the emerging market needs for Deloitte clients in the self-service analytics and insights delivery domain.
Tableau Software, Inc., together with its auxiliaries, provides business analytics software products in the United States, Canada, and internationally. The company offers Tableau Desktop, a self-service analytics environment that empowers people to access and analyze data independently; and Tableau Server, a business intelligence platform with data administration, scalability, and security to foster the sharing of data, in addition to to improve the dissemination of information in an organization and promote improved decision-making.
Shares of WestRock Co (NYSE:WRK), declined -2.15% to $56.33, during its last trading session.
Grupo Gondi and WestRock, have agreed to combine their operations in Mexico to form a joint venture, creating a leading paper and packaging company in the country.
Grupo Gondi presently operates ten production sites that hold six paper machines, seven corrugated packaging plants and four modern high graphic folding carton plants with pre-printing capacity.
WestRock, one of the world’s leading companies in the paper and packaging industry, operates three facilities in Mexico that produce corrugated packaging. WestRock will contribute these facilities, located in Mexicali, Monterrey and Queretaro, and cash to the joint venture in exchange for a 25 percent equity participation in the combined entity, which will operate as Grupo Gondi.
WestRock Company manufactures and sells paper and packaging solutions for consumer and corrugated markets in North America, South America, Europe, and the Asia-Pacific. It offers folding cartons for use in various food and non-food applications; superior pumps, sprayers, and dispensing closures for home cleaning, healthcare, and beauty and personal care products; and corrugated containers for home appliances, electric motors, small machinery, produce, books, furniture, and other products.
Finally, Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), ended its last trade with -2.16% loss, and closed at $11.34.
Lexicon Pharmaceuticals, declared that data from the TELESTAR Phase 3 clinical study of telotristat etiprate has been accepted for presentation at the North American Neuroendocrine Tumor Society annual symposium to be held from October 15-17, in Austin, Texas. In addition, data from interviews with patients who accomplished the randomized treatment portion of the TELESTAR study will be presented for the first time in a poster session.
Telotristat etiprate, which has received Fast Track and Orphan Drug designation from the U.S. Food and Drug Administration, is in development for the treatment of carcinoid syndrome in cancer patients whose symptoms are not adequately controlled by long-acting somatostatin analog therapy, the current standard of care.
The oral presentation, entitled “Results of TELESTAR: A Phase 3, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate in Patients with Carcinoid Syndrome Not Adequately Controlled by Somatostatin Analog,” will be presented at the Clinical Science Symposium at 8:30 a.m. CDT, on October 16, by primary investigator, Matthew H. Kulke, M.D., Director, Program in Neuroendocrine and Carcinoid Tumors and Senior Physician, Dana Farber Cancer Institute, and Associate Professor of Medicine, Harvard Medical School.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human diseases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
